Metabolic gene polynucleotides and polypeptides and uses thereof
US7348406B2 · kind B2 · utility
0Cited by
7References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2002 |
| Grant date | Mar 25, 2008 |
| Priority date | — |
| Expiry date | Sep 22, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2217/075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.